Apimeds Pharmaceuticals US, Inc.

Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.

APUS | US

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 100 MATAWAN RD, 7747 MATAWAN
Website:: https://www.apimedsus.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat inflammation and pain. The company's lead program is Apitox, a novel, non-narcotic therapy derived from purified honey bee venom. Apitox is being clinically studied for treating pain and inflammation, particularly in patients with osteoarthritis. Apimeds operates on a principle it calls 'Actual Intelligence (ai²™),' which emphasizes human experience, scientific rigor, and clinical judgment to identify and develop overlooked or distressed clinical assets. This approach guides the company in navigating regulatory, intellectual property, and market access challenges, with a primary commitment to patients and physicians.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Apimeds Pharmaceuticals US, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Apimeds Pharmaceuticals US, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Apimeds Pharmaceuticals US, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Kura Oncology, Inc. Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.	United States of America	KURA
KWANGDONG PHARMACEUTICAL CO.,LTD Developing drugs & health goods by integrating oriental and Western medicine.	South Korea	009290
Kyivmedpreparat A leading pharmaceutical producer of antibacterial, generic, and original medicines in various forms.	Ukraine	KMED
KYONGBO PHARMACEUTICAL CO., LTD. Manufactures APIs and finished drugs, offering global CDMO services from development to production.	South Korea	214390
KYORIN Pharmaceutical Co., Ltd. Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.	Japan	4569
Kyowa Kirin Co.,Ltd. Develops antibody medicines for oncology, nephrology, immunology, and allergy.	Japan	4151
KyungdongPharm Develops and manufactures Rx/OTC drugs & APIs for cardiology and other chronic conditions.	South Korea	011040
KYUNG NAM PHARM.CO.,LTD. South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.	South Korea	053950
Kyverna Therapeutics, Inc. Developing CAR T-cell therapies for durable remission in autoimmune diseases.	United States of America	KYTX
Labiana S.A. Pharmaceutical CDMO for animal & human health with its own line of vaccines and generics.	Spain	LAB